Driehaus Capital Management LLC Acquires Shares of 66,667 Contineum Therapeutics, Inc. (NASDAQ:CTNM)

Driehaus Capital Management LLC purchased a new position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) during the second quarter, HoldingsChannel.com reports. The fund purchased 66,667 shares of the company’s stock, valued at approximately $1,174,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Sandia Investment Management LP bought a new position in shares of Contineum Therapeutics in the second quarter worth approximately $88,000. Rhumbline Advisers bought a new position in shares of Contineum Therapeutics in the second quarter worth approximately $118,000. Bank of New York Mellon Corp bought a new position in shares of Contineum Therapeutics in the second quarter worth approximately $356,000. Squarepoint Ops LLC bought a new position in shares of Contineum Therapeutics in the second quarter worth approximately $2,642,000. Finally, Versant Venture Management LLC bought a new position in shares of Contineum Therapeutics in the second quarter worth approximately $16,169,000.

Wall Street Analysts Forecast Growth

Separately, Royal Bank of Canada raised their price target on Contineum Therapeutics from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 14th.

Contineum Therapeutics Stock Up 0.9 %

Shares of Contineum Therapeutics stock opened at $18.84 on Monday. The firm’s fifty day moving average price is $18.73. Contineum Therapeutics, Inc. has a 12 month low of $13.27 and a 12 month high of $22.00.

Contineum Therapeutics (NASDAQ:CTNM) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.02). Sell-side analysts anticipate that Contineum Therapeutics, Inc. will post -2.04 EPS for the current year.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).